Early Detection is Likely Reason That Metastatic Prostate Cancer Cases Declined, Study Shows

Early Detection is Likely Reason That Metastatic Prostate Cancer Cases Declined, Study Shows
Early detection of prostate cancer has led to a reduction in the number of men with metastatic cancer over time, researchers found in a population-based study analyzing patients in the U.S. and Denmark. The study findings were presented at the European Association of Urology Congress 2018 (EAU2018) in Copenhagen, Denmark, in a lecture titled “Incidence and survival trends of de-novo metastatic prostate cancer - a population-based analysis of two national cohorts from USA and Denmark”. The team analyzed metastatic prostate cancer incidence in two large groups of patients from the U.S. and Denmark: 29,555 men registered at the Surveillance, Epidemiology and End Results (SEER), and diagnosed from 1980 to 2011, and 6,874 men included in the Danish Prostate Cancer Registry (DaPCaR), and diagnosed from 1995 to 2011. Patients were grouped according to the time they were diagnosed, and each group was analyzed separately and compared to the others. In the SEER group, the largest and longest one, the incidence of metastatic prostate cancer dropped from 12.0 cases per 100,000 men from 1980 to 1984, to 4.4 cases per 100,000 men from 2005 to 2011. Contrarily, the Danish DaPCaR group revealed an increase from 6.7 cases per 100,000 men from 1995–1999, to 9.9 per 100,000 from 2005–2011.   Although these results might seem to be contradictory, the decline in metastatic disease observed in the American population is expected to be the case in Denmark in the relatively near future, researchers predict. “Our findings from the US population suggest that prostate cancer-specific mortality is highly affected by the incidence of de novo metastatic disease. If the patterns of incidence continue to mimic the American [data], a drop in prostate cancer-specific mor
Subscribe or to access all post and page content.